Evidence map›Paper›PMID 40982113›Full record

ReviewDiscover oncology2025

KLF4 in cancer chemoresistance: molecular mechanisms and therapeutic implications.

Suresh Singh Yadav, Punita Kalia, Navneet Kaur, Sourav Sharma, Shambhavi Thakur, Soni Kumari, Rohini Ravindran Nair

Abstract readReview
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Suresh Singh YadavDepartment of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, Punjab, 143005, India. suresh4bhu@gmail.com.
Punita KaliaDepartment of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, Punjab, 143005, India.
Navneet KaurDepartment of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, Punjab, 143005, India.
Sourav SharmaDepartment of Medical Biotechnology, Gujarat Biotechnology University, Gandhinagar, Gujarat, 382355, India.
Shambhavi ThakurDepartment of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, Punjab, 143005, India.
Soni KumariDepartment of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.
Rohini Ravindran NairDepartment of Medical Biotechnology, Gujarat Biotechnology University, Gandhinagar, Gujarat, 382355, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoresistance is a major obstacle in cancer treatment, and it often results in treatment failure and disease progression. Among the plethora of factors contributing to chemoresistance, the transcription factor Krüppel-like factor 4 (KLF4) has emerged as a pivotal player. This review discusses the role of KLF4 in orchestrating various mechanisms underlying cancer chemoresistance. KLF4, originally identified as a regulator of cell differentiation and proliferation, has recently gained attention for its role in modulating cellular responses to chemotherapeutic agents. Through complex regulatory networks, KLF4 modulates the process of drug efflux, DNA repair, apoptotic signaling, tumor heterogeneity, and cancer cell stemness, leading to the development of cancer chemoresistance. Additionally, tissue or cell types specific post-translational modification (PTM) of KLF4 plays a significant role in the development of cancer chemoresistance. The review explores emerging possibilities and available information that can be utilised to understand the mechanism of chemoresistance mediated by KLF4 in cancer. In conclusion, understanding the complex mechanisms through which KLF4 orchestrates cancer chemoresistance opens promising avenues for developing more effective therapeutic interventions to combat treatment-resistant cancers.

Indexed as

CancerChemoresistanceDNA repairDrug effluxKLF4Post-translational modificationTumor heterogeneity

Identifiers

PMID40982113
PMCPMC12454242

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.